- Home
- HKD vs URGN Comparison
HKD vs URGN Comparison
Compare HKD & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HKD
- URGN
- Stock Information
- Founded
- HKD 2003
- URGN 2004
- Country
- HKD France
- URGN United States
- Employees
- HKD N/A
- URGN N/A
- Industry
- HKD Finance: Consumer Services
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- HKD Finance
- URGN Health Care
- Exchange
- HKD Nasdaq
- URGN Nasdaq
- Market Cap
- HKD 447.7M
- URGN 463.2M
- IPO Year
- HKD 2022
- URGN 2017
- Fundamental
- Price
- HKD $2.08
- URGN $10.38
- Analyst Decision
- HKD
- URGN Strong Buy
- Analyst Count
- HKD 0
- URGN 7
- Target Price
- HKD N/A
- URGN $36.75
- AVG Volume (30 Days)
- HKD 119.8K
- URGN 651.7K
- Earning Date
- HKD 01-01-0001
- URGN 05-12-2025
- Dividend Yield
- HKD N/A
- URGN N/A
- EPS Growth
- HKD 9.93
- URGN N/A
- EPS
- HKD 0.23
- URGN N/A
- Revenue
- HKD $20,445,000.00
- URGN $90,398,000.00
- Revenue This Year
- HKD N/A
- URGN $36.82
- Revenue Next Year
- HKD N/A
- URGN $119.10
- P/E Ratio
- HKD $9.20
- URGN N/A
- Revenue Growth
- HKD N/A
- URGN 9.29
- 52 Week Low
- HKD $1.65
- URGN $8.94
- 52 Week High
- HKD $5.80
- URGN $20.70
- Technical
- Relative Strength Index (RSI)
- HKD 50.48
- URGN 48.46
- Support Level
- HKD $1.98
- URGN $9.63
- Resistance Level
- HKD $2.18
- URGN $11.75
- Average True Range (ATR)
- HKD 0.12
- URGN 0.82
- MACD
- HKD 0.02
- URGN -0.02
- Stochastic Oscillator
- HKD 62.16
- URGN 32.90
About HKD AMTD Digital Inc. (every five of which represent two)
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. The company integrates various digital businesses using its AMTD SpiderNet ecosystem. Its reportable segments are; digital solutions services financial services; digital solutions services non-financial services, hotel operations, hospitality and VIP services, digital media, content and marketing services, and others. The company generates maximum revenue by providing financial digital solutions through its AMTD Risk Solutions, a digital insurance brokerage platform, and PolicyPal which is a digital insurance technology platform. Geographically, the company generates maximum revenue from Hong Kong and the rest from Canada and Singapore.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.